Summary The distribution of iodine-131 (I31I) labelled antibody to carcinoembryonic antigen (CEA) has been studied in 16 patients with colorectal cancer. Levels of tumour and normal tissue radioactivity were measured by serial gamma-camera imaging and counting of blood and urine. Maximum concentrations were found in tumour 8h after administration and varied up to 9-fold in different patients. Higher levels were found on average in tumour than in any other tissue. Liver, lung and blood were the other tissues in which antibody was concentrated relative to the rest of the body. Antibody cleared from all these tissues over 1 week. Second antibody directed against the antitumour (first) antibody was given 24h after first antibody in order to accelerate clearance from the blood. This increased the tumour to blood ratio but had little effect on other tissues. Cumulative radiation dose to tumour and normal tissue was estimated. In patients with the most efficient localisation the tumour to body ratio was 20:1 and tumour to blood ratio 5:1. This may be sufficient for effective therapy of cancer in patients selected for efficient antibody localisation. The data may be used to estimate the effect of different therapeutic strategies. For instance, in the time after second antibody administration the average tumour to blood ratio of radiation dose was 11:1, suggesting that two phase systems in which the therapeutic modality is given after a good tumour to normal tissue ratio is obtained may be effective for the majority of patients.
Antibody targeted therapy of cancer requires that a favourable distribution of antibody is sustained in tumour relative to normal tissues. Favourable distributions have been shown in mice bearing xenografts of human tumours (Sharkey et al., 1987; Buchegger et al., 1988; Begent et al., 1987) and an antitumour effect is achieved in these systems (Goldenberg et al., 1981; Sharkey et al., 1987; Zalcberg et al., 1984; Jones et al., 1985; Buchegger et al., 1988; Lee et al., 1988; Wakabayashi, 1984; Chiou et al., 1988; Badger et al., 1986; Ceriani & Blank, 1988) . Although responses are reported in patients treated systemically with 131I-labelled antitumour antibodies Lenhard et al., 1985; Carrasquillo et al., 1984; Rosen et al., 1987; DeNardo et al., 1988) these have not been sufficient for other forms of therapy to be replaced. Understanding the reasons for this depends on a knowledge of the time course of antibody distribution in man which is lacking.
Gamma-camera imaging has given some serial measurements of radioactivity in tissues of patients receiving 1311-labelled antibody (Leichner et al., 1981; Hammond et al., 1984; Carrasquillo et al., 1984) . However, observations were made at few time points and there were no data from the first 24h when activity may be highest. The planar imaging method used (Thomas et al., 1976 ) is reasonably accurate when there are no overlying tissues with significant levels of activity but is unsatisfactory for measuring activity in tumours or other organs lying deep in the body. This paper describes the use of a gamma-camera system to assess antibody distribution in tumour and normal tissues throughout the time course of therapy. Single photon emission tomography (SPET) (Riggs et al., 1988) was used to give three-dimensional data for quantitation of radioactivity where planar imaging was inadequate. Patients with colorectal cancer were studied after receiving 1311 antibody to CEA and cumulative radiation doses calculated. The effect of second antibody to accelerate clearance of the antitumour antibody from the blood (Begent et al., 1982 (Begent et al., , 1987 and the effect of increasing the amount of antibody administered were investigated. 
Methods

Antibodies
PK4S sheep anti-CEA antibody, affinity purified by elution from a column of CEA bound to Sepharose, has been described previously (Begent et al., 1986a (Begent et al., , 1987 . Antibody was radiolabelled by the chloramine T method over ice to a specific activity of 15.2-24mCimg-1 antibody (median 19.4). After radiolabelling, reactivity of the antibody was confirmed by reacting it with CEA on a nitrocellulose disc. Binding was shown by autoradiography after washing the disc. Horse anti-goat or donkey anti-sheep second antibody was prepared as described previously (Begent et al., 1987) and 4.0-5.3 (median 4.8) times the amount of protein of the first antibody was given. Antibodies were prepared in accordance with the Operation Manual for Control of Production, Preclinical Toxicology and Phase 1 Trials of Antitumour Antibodies and Drug Antibody Conjugates (1986) .
Human anti-sheep and human anti-donkey antibody were measured by enzyme immunoassay as described by Ledermann et al. (1988) for human anti-mouse antibody.
Patients
Patients had unresectable local recurrent or metastatic carcinoma of the colon or rectum. With ethical committee approval and after obtaining signed written consent, the following protocol was commenced. detectable in the vial. Three litres of saline 0.9% alternating with dextrose 5% infused intravenously daily for 3 days to ensure rapid clearance of 1311 from the urinary tract.
Day I One hour after oral administration of 600mg soluble aspirin and 8mg chlorpheniramine, 10% of the second antibody was given intravenously over 10min. If there was no reaction after 20 min, the remainder of the second antibody was given over 20min.
Toxicity to patients was measured using WHO criteria (WHO, 1979) .
Estimation of tissue activity and cumulative radiation dose Whole blood reactivity was measured with an LKB Compugamma in samples taken 20min and 6h after 1311 antibody, immediately before and 2h after second antibody and then on days 2, 3, 4, 6, 13 and 20. Whole body activity was estimated by subtracting cumulative urine activity (LKB Compugamma) from the administered activity.
Activity in other organs was determined by gammacamera imaging with the whole body scanning facility of the IGE Gemini gamma-camera. A high resolution 400 keV collimator with a full width half maximum (FWHM) of 11.2 mm at 100 mm in air was used for most of the work. A second 400 keV collimator with a FWHM of 14.1 mm at 100mm in air and a sensitivity of 3 times that of the first collimator was used for imaging at later times. Before therapy an attenuation map of the patient was made with the gamma-camera above the patient couch and a flood source containing approximately 5mCi 1311 suspended from the gamma-camera to hang beneath the patient and move with the camera. Images were taken with and without the patient in position so that attenuation of the whole body could be mapped. Opposed views of the body were then taken at approximately 6, 28, 54, 72, 144 and 216h after antibody injection. The method of Thomas et al. (1976) was used to estimate organ activities at these times. In some patients serial tomographic studies were performed and activities calculated as described by Riggs et al. (1988) . Activities in tumour lying behind other organs, such as the bladder, were calculated in this way.
Clearance curves were calculated by fitting double exponential curves to these serial estimates of blood and organ activity. Cumulated dose was calculated from integration of the clearance curves and estimates of tumour volume obtained from X-ray computerised tomography scans.
Results
Four groups were studied: (1) Antibody concentration is seen in tumour, blood, liver and the lungs. The rest of the body had lower levels except for the spleen which occasionally showed concentration as detailed below. Activity was also seen in the urinary tract but represents 131I separated from the antibody. No attempt was made to quantitate activity in areas of low activity where statistical error inherent in the low count rates would compromise the validity of activity measurements. Blood activity Activity in blood fell rapidly so that tumour and liver values exceeded it by 8 h (Table I ). This may have resulted from antibody uptake in these tissues. Second antibody accelerated clearance from the blood, improving tumour to blood ratios at all three levels of administered activity. Second antibody produced a marked effect on blood within 2h as shown in Figure 1 . Antibody-bound 1311, estimated by measuring the proportion of counts precipitated by addition of an equal volume of 20% trichloracetic acid, was 72.6% (standard deviation 19.4) 66-72h after injection in the five patients in whom it was studied.
Tumour activity
This was on average higher than any other tissue although considerable variation occurred between patients, as indicated by the high standard deviations. Activity in tumour was highest 8h after antibody administration and fell at a rate similar to other tissues with high activity (Table I ). An example of the best localisation without second antibody is shown in Figure 2a . A gamma-camera image of this tumour is shown in Figure 2b . The best localisation seen with second antibody is shown in Figure 3 . 
Liver and lung activity
This antibody localises to liver in areas which appeared to be tumour-free and to a lesser extent in lung (Table I ). The activity did not fall after second antibody indicating that the effect was not caused by blood located in the liver vasculature. No rise was seen in liver activity after second antibody administration (Table I) .
Cumulative radiation dose Mean beta doses to various tissues derived from the data in Table I without decay correction are shown in Table II . Without second antibody the tumour to blood dose ratio was 1.8:1 but ratios were less favourable for liver, lung arnd spleen. The tumour to whole body ratio of 4.5:1 reflected lower activity in most other parts of the body. The use of second antibody reduced the dose to blood though the difference did not reach statistical significance. The tumour to blood ratio increased to 2.5:1 but there was a small reduction in tumour dose. Clearance of 131I through the liver by second antibody did not increase the dose to this organ. Doses to the spleen recorded by planar imaging were higher than other organs. SPET gave much lower values (Table III) Effect of second antibody Although overall doses were not significantly reduced by second antibody, the part of the dose delivered to the blood more than 48 h after anti-CEA antibody administration (24 h after second antibody) is less with second antibody than without (significant at the 5% level by the Mann-Whitney U test). The result is a usefully improved mean tumour to blood ratio of 11:1 as shown in Table IV .
Toxicity
The toxicity recorded in 11 patients receiving second antibody at various levels of administered activity together with five control patients not receiving second antibody only is shown in Table V . Haematological toxicity was the only effect related to administered activity seen. Rigors occurred in some patients and this was eliminated after a change in chromatography equipment near the end of the study. There was no liver or lung toxicity although these organs received doses as high as or higher than blood through which marrow dose is thought to be given. This suggests that marrow is more radiosensitive than the other organs.
Response
The patient with the most favourable radiation dose to tumour (Figure 2) Hb, haemoglobin (gdl-1); WBC, total white blood cell count (x 109 1-1); plat, platelets (x 1091-1); N/V, nausea or vomiting. accurate because of the count rate with therapeutic amounts of administered activity of 131I (Riggs et al., 1988) .
Although measurement of 1311 levels is not an absolute indication of antibody localisation because of de-iodination of antibody, it gives the best representation available for clinical studies. Indium-111-labelled antibodies, for example, lead to prolonged retention of radionuclide in normal liver and bone.
The finding of higher levels of activity in the tumour than blood or other normal tissues as soon as 8h after administration was associated with progressive clearance from blood and tumour over the next 6 days. This pattern differs from that of the same antibody in nude mice bearing human colon carcinoma xenografts. The animals showed slower blood clearance and the antibody continued to accumulate in tumours for 2 days or more (Begent et al., 1987) . The concentration of antibody in the tumour only exceeded that in blood after 8 days. The more rapid blood clearance of antibody in man would tend to give an earlier peak uptake of antibody in tumour. This is consistent with the findings with F(ab')2 fragments of antibody in animals which are cleared rapidly from the circulation. The tumour to blood ratios are high at early times and antibody then clears from the tumour (Harwood et al., 1987) . Second antibody is thought to clear first antibody through the liver but an increase in liver activity was not seen after second antibody administration. This is probably because 1311 antibody had been cleared from the liver by the time of gamma-camera imaging 5-6h after second antibody administration.
The variation in tumour uptake between individuals was striking, the highest having 9.6 times the concentration of the lowest at 8h. This-variability is also expressed in the high standard deviations of tumour activities compared with the more reproducible distribution in normal tissues. For individual patients, however, tumour activity followed a predictable decline with time suggesting that the variation is the result of different characteristics of different tumours rather than inaccuracies in measurement of activity by the gammacamera. This is supported by the validation of the SPET method used for tumour activity measurement (Riggs et al., 1988) . Other studies have shown considerable variation in the uptake of antibodies in tumour (Mach et al., 1980; Leichner et al., 1984; Begent et al., 1986a; Estaban et al., 1987) . This is therefore likely to be of major importance in selection of patients for antibody therapy. A method of quantitating tumour localisation of antibody is likely to be needed for selection of individual patients for any form of antibody targeted therapy.
Applying these data about antibody distribution to the example of therapy with the beta emission of 1311, measurements of cumulative radiation dose to tumour and normal tissues can be made to assess the possibilities for effective therapy. The patient with the highest tumour activity had a beta radiation dose to tumour of 5.1 cGy mCi -1 injected with a whole body dose of 0.25 cGy mCi -1, a ratio of 20.4:1. Dykes et al. (1987) have predicted that a ratio of 30:1 is needed for effective therapy assuming that a whole body dose of 200cGy is tolerable. By these criteria effective therapy may be in range for some patients, particularly with repeated antibody administration as is now possible by use of cyclosporin A to prevent the human anti-antibody response (Ledermann et al., 1988) . For the majority, however, effective therapy would not appear practical with this antibody.
The model of Dykes et al. (1987) , on which the assumptions above are based, does omit factors which are worthy of consideration. Bone marrow radiation dose is probably more relevant than whole body dose as the factor limiting administered activity. This would be in keeping with data from whole body irradiation by an external beam and from therapy with 1311 antibody (Carrasquillo et al., 1984; Leichner, 1981) . The data of Benua et al. (1962) for 131I therapy of thyroid cancer indicate that a radiation dose to blood of 200cGy will produce myelosuppression from which recovery is predictable.
It is evident that tumour to blood ratios are less favourable than those for tumour to body. Using the mean tumour and blood radiation doses for patients without second antibody from Table II , a tumour dose of 360cGy would be given for a blood dose of 200 cGy. The best patient, however, would receive a tumour dose of 1,020cGy. With second antibody the mean tumour dose would be 500cGy and the best 1,345 cGy. Responses of cutaneous T-cell lymphoma and B-cell lymphoma have been reported with 131I-labelled antibody therapy delivering a tumour dose estimated between 500 and 100 cGy (Rosen et al., 1987; DeNardo et al., 1988) . Lymphoma is more radiosensitive than colorectal cancer but it is interesting that the patient in the present study with the highest radiation dose to tumour of 306 cGy had a short-lived partial response (Figure 4 ). These responses are perhaps better than might be expected with external beam radiotherapy and may be the result of an underestimate of dose delivered to cancer cell nuclei. The microscopic distribution of antibody within the tumour mass favours localisation on and around tumour cells relative to stromal and necrotic areas of tumour as discussed previously (Begent et al., 1986b) . The extent of the advantage produced by this factor is unknown but if it is 5-fold a possibly tumoricidal dose of 6.725 cGy could be delivered with a single therapy to the patient with the most favourable distribution if the administered activity was, increased until the blood received 400 cGy. This factor may vary with different tumour types; the extensive stromal and mucinous areas common in colon carcinoma will separate cells to which antibody may bind specifically giving a lower apparent concentration of antibody than in a tumour of tightly packed tumour cells such as hepatoma. This may explain the apparently higher tumour doses achieved by Order et al. (1985) in hepatoma.
A higher bone marrow dose might be acceptable with appropriate facilities to support a myelosuppressed patient.
It is likely that recovery would be usual with 400 cGy to bone marrow and that higher doses would be tolerable with autologous bone marrow transplantation.
In humans the maximum administered activity will then depend on the tolerance of other normal tissues. In the example shown here the liver receives the highest dose of any normal tissue followed by the lung. It is interesting that liver and lung were the tissues in which the greatest flux of antibody was predicted by the model of Covell et al. (1986) . These organs would probably be damaged with sufficient escalation of administered activity. The failure to find any hepatic toxicity may be because of lower intrinsic radiosensitivity in the liver than the bone marrow. The antibodies did not react with normal human liver by immunohistochemistry which does not suggest a specific reaction with an antigen on normal liver cells. Clearance of immune complexes formed between antibody and circulating CEA via the liver is a further possibility.
The purpose of giving second antibody was to investigate whether the radiation dose to bone marrow could be reduced permitting a higher tumour dose to be given. Although blood activity was significantly reduced after second antibody administration, this had only a small effect on the cumulative radiation dose, most of which had already been given before second antibody administration. Activity was reduced less in the tumour than in blood after second antibody and this raises the possibility that the favourable tumour to blood ratio after this could be exploited. The mean ratio of cumulative radiation dose after second antibody was 11:1, which offers a favourable therapeutic ratio for the majority of patients. This could be exploited by two phase systems in which the therapeutic agent is given after the antitumour antibody and localises to antibody already on the tumour (Raso, 1982) or is activated at the tumour site by an enzyme linked to antibody .
Measurements of antibody distribution over a period of time after administration identify the favourable and unfavourable features of antibody therapy. The influence of modifications such as escalation of administered activity and the use of second antibody can be quantitated. Although the methods for dosimetry are laborious the results enable work to be directed to overcoming the problems and exploiting the opportunities which have been identified.
